Akebia Therapeutics Inc (AKBA)
1.36
-0.03
(-2.16%)
USD |
NASDAQ |
Apr 19, 16:00
1.355
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Profit Margin (Quarterly): 1.09% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.09% |
| September 30, 2023 | -34.46% |
| June 30, 2023 | -19.82% |
| March 31, 2023 | -65.34% |
| December 31, 2022 | -10.88% |
| September 30, 2022 | -111.0% |
| June 30, 2022 | 23.30% |
| March 31, 2022 | -101.2% |
| December 31, 2021 | -121.1% |
| September 30, 2021 | -122.1% |
| June 30, 2021 | -156.9% |
| March 31, 2021 | -133.0% |
| December 31, 2020 | -157.7% |
| September 30, 2020 | -99.95% |
| June 30, 2020 | -195.0% |
| Date | Value |
|---|---|
| March 31, 2020 | -68.66% |
| December 31, 2019 | -135.8% |
| September 30, 2019 | -59.35% |
| June 30, 2019 | -57.71% |
| March 31, 2019 | -99.66% |
| December 31, 2018 | -100.3% |
| September 30, 2018 | -48.99% |
| June 30, 2018 | -69.82% |
| March 31, 2018 | -50.99% |
| December 31, 2017 | 17.14% |
| September 30, 2017 | -56.04% |
| June 30, 2017 | -75.45% |
| March 31, 2017 | -213.5% |
| December 31, 2016 | -2.47K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-195.0%
Minimum
Jun 2020
23.30%
Maximum
Jun 2022
-85.56%
Average
-99.95%
Median
Sep 2020
Profit Margin (Quarterly) Benchmarks
| Ocugen Inc | -157.3% |
| Aquestive Therapeutics Inc | -61.42% |
| SELLAS Life Sciences Group Inc | -- |
| Protagonist Therapeutics Inc | 45.56% |
| Stoke Therapeutics Inc | -962.1% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -18.80% |
| Return on Invested Capital | -196.8% |
| Gross Profit Margin (Quarterly) | 66.79% |
| Operating Margin (Quarterly) | 2.44% |
| Return on Net Operating Assets | -27.93% |